NYSE:ZTSPharmaceuticals
Zoetis Faces Fraud Probe As Burry Backs Dividend-Paying Animal Health Firm
A securities law firm has launched an investigation into Zoetis (NYSE:ZTS) over potential securities fraud tied to its revised 2026 outlook.
The probe follows a guidance cut that arrived only weeks after management comments that pointed to resilience.
At the same time, value investor Michael Burry has disclosed a new position in Zoetis, calling the company overlooked and high quality.
Zoetis, a large player in animal health products and vaccines, now sits at the intersection of legal...